Moderna (MRNA) Receivables (2017 - 2026)

Moderna (MRNA) has reported Receivables for 10 consecutive years, with $160.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 50.16% year-over-year to $160.0 million in Q2 2026; TTM through Jun 2026 was $160.0 million, a 50.16% decrease from a year earlier, with the FY2025 full-year figure at $410.0 million, down 45.84% from the prior year.
• Receivables was $160.0 million for Q2 2026 at Moderna, down from $242.0 million in the prior quarter.
• Over five years, Receivables peaked at $3.2 billion in Q1 2022 and troughed at $160.0 million in Q2 2026.
• A 5-year average of $1.3 billion and a median of $969.5 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables plunged 89.3% in 2023 and surged 86.39% in 2024, its largest moves.
• Over 5 years, Receivables stood at $1.4 billion in 2022, then climbed by 13.62% to $1.6 billion in 2023, then slumped by 53.93% to $757.0 million in 2024, then tumbled by 45.84% to $410.0 million in 2025, then slumped by 60.98% to $160.0 million in 2026.
• The last three Receivables figures came in at $160.0 million (Q2 2026), $242.0 million (Q1 2026), and $410.0 million (Q4 2025), per Business Quant data.